Brief: Akanda To Supply Tetra Bio-Pharma With Pharmaceutical-Grade Cannabis For FDA Trials Of Qixleef, A Potential Multimillion Dollar Prescription Drug

Tetra Bio Pharma

12/07/2022 12:40

July 12 (Reuters) - Tetra Bio Pharma Inc  TBP.TO :
    * AKANDA TO SUPPLY TETRA BIO-PHARMA WITH
PHARMACEUTICAL-GRADE
CANNABIS FOR FDA TRIALS OF QIXLEEF™, A POTENTIAL MULTIMILLION
DOLLAR PRESCRIPTION DRUG
    * AKANDA CORP - WILL ACT AS A CONTRACT DEVELOPMENT AND
MANUFACTURING ORGANIZATION (CDMO) FOR TETRA'S CLINICAL DRUG AND
COMMERCIAL SUPPLY PROGRAMS
    * AKANDA CORP - UNDER MULTI-YEAR AGREEMENT, CO WILL SUPPLY
TETRA
WITH HIGH-QUALITY, PREMIUM THC AND CBD FLOWER
    * AKANDA - WILL PROVIDE TETRA WITH REGULATORY AFFAIRS,
QUALITY
CONTROL & STABILITY TESTING THROUGH CO'S INTERNAL LAB &
MANUFACTURING CAPABILITIES
    * AKANDA CORP - UPON FDA APPROVAL, ANTICIPATED SUPPLY
COMMITMENTS
COULD REACH [OVER 10 METRIC TONNES] PER YEAR
    * AKANDA CORP - UNDER AGREEMENT, CO WILL PROVIDE REGULATORY,
QUALITY & PHARMACEUTICAL MANUFACTURING SERVICES FOR QIXLEEF(TM)
CLINICAL DRUG DEVELOPMENT

Source text for Eikon:  ID:nPnc93vTWa 
Further company coverage:  TBP.TO 

 ((Reuters.Briefs@thomsonreuters.com;))